To ensure the best possible experience for all members, we have established some basic guidelines for participation. By joining and using this community, you agree that you have read and will follow these rules and guidelines. You also agree to reserve discussions and shared files and content to that are best suited to the medium.
This is a great medium with which to solicit the advice of immunotherapy for prostate cancer peers, benefit from their experience, and participate in an ongoing conversation. Questions should be directed to our Membership Department via the Contact Staff link on this site. Technical questions on association management issues should directed to our help desk via email at info sitcancer.
Please take a moment to acquaint yourself with these important guidelines.
If you have questions, contact the help desk. In order to preserve a climate that encourages both civil and fruitful dialogue, we reserve the right to suspend or terminate membership in this community for anyone who violate these rules.
The Rules Do not challenge or attack others. The discussions and comments are meant to stimulate conversation not to create contention. Let others have their say, just as you may. Do not post commercial messages on any discussion list, resource library entry, or other area where others might see it. Contact people directly with product and service information if you believe it would help them. Use caution when discussing products. Information posted on the lists and in the libraries is available for all to see, and comments are subject to libel, slander, and antitrust laws.
All defamatory, abusive, profane, threatening, offensive, or illegal materials are strictly prohibited. Do not post anything that you would not want the world to see or that you would not want anyone to know came from you.
Please note carefully all items listed in the disclaimer and legal rules below, particularly regarding the copyright ownership of information posted. Remember that other participants have the right to reproduce postings to this site unless you specify otherwise. Post your immunotherapy for prostate cancer or documents only to the most appropriate lists or libraries.
World Lung Cancer Day Fact Sheet - American College of Chest Physicians
Do not spam several lists or libraries with the same message. All messages must add to the body of knowledge.
Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival.
We reserve the right to reject any message for any reason. Discussion Group Etiquette Include a signature tag on all messages. Include your name, affiliation, location. State concisely and clearly the topic of your comments in the subject line.
This allows members to respond more appropriately to your posting and makes it easier for members to search the archives by subject. Include only the relevant portions of the original message in your reply. Delete any header information, and put your response before the original posting.
Only send a message to the entire list when it contains information that everyone can benefit from. Send messages such as "thanks for the information" or "me, too" to individuals--not to the entire list.
Do this by using the "Reply to Sender" link to the left of every message. Do not send administrative messages, such as remove me from the list. Instead, use the web interface to change your settings or to remove yourself from a list.
The has a broad clinical and pre-clinical product pipeline. Our differentiated pipeline stands as proof of our ability to identify and address the areas of unmet treatment need and includes three Genmab-created antibodies, out-licensed and developed by partners, that were approved by the U. Food and Drug Administration with breakthrough designations—Daratumumab, Ofatumumab and Teprotumumab www.
If you are changing e-mail addresses, you do not need to remove yourself from the list and rejoin under your new e-mail address. Simply change your settings. Warn other list subscribers of lengthy messages either in the subject line or at the beginning of the message body with a line that says "Long Message.
Society for Immunotherapy of Cancer is not responsible for the opinions and information posted on this site by others. We disclaim all warranties with regard to information posted on this site, whether posted by Society for Immunotherapy of Cancer or any third party; this disclaimer includes all implied warranties of merchantability and fitness.
In no event shall Society for Immunotherapy of Cancer be liable for any special, indirect, or consequential damages or any damages whatsoever resulting from loss of use, data, or profits, arising out of or in connection with the use or performance of any information posted on this site.
[Immunotherapy in the treatment of genitourinary cancers]
Do not post any defamatory, abusive, profane, threatening, offensive, or illegal materials. Do not post any information or other material protected by copyright without the permission of the copyright owner. By posting material, the posting party warrants and represents that he or she owns the copyright with respect to such material or has received permission from the copyright owner. In addition, the posting party grants Society for Immunotherapy of Cancer and users of this site the nonexclusive right and license to display, copy, publish, distribute, transmit, print, and use such information or other material.
Messages should not be posted if they encourage or facilitate members to arrive at any agreement that either expressly or impliedly leads to price fixing, a boycott of immunotherapy for prostate cancer business, or other conduct intended to illegally restrict free trade.
Messages that encourage or facilitate an agreement about the following subjects are inappropriate: prices, discounts, or terms or conditions of sale; salaries; profits, profit margins, or cost data; immunotherapy for prostate cancer shares, sales territories, or markets; allocation of customers or territories; or selection, rejection, or termination of customers or suppliers. Society for Immunotherapy of Cancer does not actively monitor the site for inappropriate postings and does not on its own undertake editorial control of postings.
However, in the event that any inappropriate posting is brought to the attention of Society for Immunotherapy for prostate cancer of Cancer we will take all appropriate action.
World Lung Cancer Day 2020 Fact Sheet
Society for Immunotherapy of Cancer reserves the right to terminate access to any user who does not abide by these guidelines. We may share your personal information with companies including our affiliates that perform services on our behalf, for example, companies that help process credit card payments.
Он понимал речь своих собеседников безо всякого труда, и ему и в голову не приходило, что в этом заключается что-то удивительное. У Диаспара и Лиза было одно и то же лингвистическое наследие, а изобретение еще в древности звукозаписывающих устройств давным-давно обеспечило речи неколебимость форм. С видом насмешливой покорности судьбе Джирейн пожал плечами.
Our service providers are required by contract to protect the confidentiality of the personal information we share with them and to use it only to provide specific services on our behalf. Business Transfers. Your personal information may be transferred to another entity either an affiliated entity or an unrelated third party in connection with a merger, reorganization, dissolution or similar corporate event.
Government and Legal Disclosures We may disclose the personal information we collect through this Site, when we, in good faith, believe disclosure is appropriate to comply with the law or a court order or subpoena ; to prevent or investigate a possible crime, such as fraud or identity theft; to enforce our Terms and Conditions or other agreements that govern your use of this Site; or to protect the rights, property or safety of our company, our users, or others.
SITC 2020 Exhibitors
To do so, please visit your My Profile page, when logged in, to edit the information available. To control what users can see on your profile, visit your Privacy Settingslocated underneath the My Account tab of your profile page. ABC provides individuals the opportunity to opt out of receiving communications from us when we request information about the user.
We may advertise to previous visitors who have not completed a task on the Site, for example, using the contact form to make an inquiry.
- Когда я впервые покинул Диаспар, - сказал он, - я не знал, что именно надеюсь обнаружить.
- [Immunotherapy in the treatment of genitourinary cancers]
The task may appear the form of an advertisement on the Google search results page or a site in the Google Display Network. COOKIES A "cookie" is a small data text file that is placed in your browser and allows us to recognize you each time you visit this site personalization, etc.
Cookies are used to provide smoother navigation throughout the Site, such as to store a saved password; to identify user trends, such as page views; and for other internal purposes, such as to assess the effectiveness of the Site.
You have the option of setting your computer to disable cookies or to alert you when cookies are being used.
In addition other Internet sites or services that may be accessible through our site have separate data and privacy practices independent of us, and therefore we disclaim any responsibility or liability for their policies or actions. Please contact those vendors and others directly if you have any questions about their privacy policies. For any other information please contact us using the Contact Us page.